Posted by Michael Wonder on 23 Nov 2021
Isofol Medical receives FDA fast track designation for arfolitixorin in advanced colorectal cancer
23 November 2021 - Isofol Medical announced today that the U.S. FDA has granted fast track designation for the development of the Company's lead drug candidate arfolitixorin, the stabilised and biologically active pure form of folate ([6R]-MTHF), for treatment of patients with metastatic colorectal cancer.
As the first and only pure form of the folate ([6R]-MTHF) that increases 5FU-cytotoxicity, arfolitixorin is currently being evaluated in the global pivotal Phase 3 AGENT trial.
